Publications and Media
Category: Publication
Filter By
Resource Type
Therapeutic Area
June 6, 2024 | Publication|JAMA
Neoadjuvant Nivolumab Plus Chemotherapy Followed By Response-Adaptive Therapy for HPV+ Oropharyngeal Cancer
HPV
OPC
October 24, 2023 | Publication|Ann Oncol
870P Dynamic cfHPV DNA changes during induction chemotherapy as an early indicator of treatment responsiveness for locally advanced head and neck cancer patients
HNC
HPV
October 24, 2023 | Publication|Ann Oncol
886P Prospective evaluation of dynamic changes of cell-free HPV-DNA (cfHPV-DNA) in locoregional HPV associated (HPV+) oropharyngeal cancer (OPC) treated with neoadjuvant chemotherapy and response-stratified treatment
HPV
OPC
November 1, 2022 | Publication|INT J RADIAT ONCOL BIOL PHYS
Cell-Free HPV DNA Kinetics Predicted by Radiographic Response in Locoregional Viral-Associated Oropharyngeal Cancer Receiving Response-Adaptive Treatment – Exploratory Analysis of a Prospective Trial
HPV
OPC
November 1, 2022 | Publication|Int J Radiat Oncol Biol Phys
Individualized Treatment Responsiveness as Quantified by Dynamic Changes in Cell Free HPV DNA in Patients Receiving Induction Chemotherapy and Definitive Chemoradiation for HPV-Related Head and Neck Cancer
HNC
HPV
June 2, 2022 | Publication|J Clin Oncol
Dynamic cell free HPV DNA is an early measure of treatment responsiveness in patients receiving induction chemotherapy for HPV-related head and neck cancer.
HNC
HPV
April 1, 2022 | Publication|INT J RADIAT ONCOL BIOL PHYS
Evaluation of Cell-Free HPV DNA in Patients With HPV-Associated Oropharyngeal Cancer Treated With Induction Chemotherapy and Response-Adaptive Therapy
HPV
OPC
January 3, 2022 | Publication|BMC Cancer
Prospective study evaluating dynamic changes of cell-free HPV DNA in locoregional viral-associated oropharyngeal cancer treated with induction chemotherapy and response-adaptive treatment
HPV
OPC
May 28, 2021 | Publication|J Clin Oncol
Ultra-sensitive detection and quantification of HPV DNA in the plasma of patients with oropharyngeal squamous cell carcinoma (OPSCC) enrolled in the OPTIMA 2 treatment de-escalation trial.
HPV
OPSCC
May 28, 2021 | Publication|J Clin Oncol
A randomized phase III study of immune checkpoint inhibition with chemotherapy in treatment-naive metastatic anal cancer patients: A trial of the ECOG-ACRIN cancer research group (EA2176).
Anal Cancer
HPV